The first study was a proof-of-concept study in which five patients received intralesional injections of BQ788, a selective ETBR antagonist, in increasing doses into melanoma skin metastases compared with injections with phosphate buffered saline (PBS) into different skin lesions of the same patient [111]. Here, EDNRB is linked to melanoma.